Skip to main content

Amneal launches biosimilar Avastin

Amneal’s Alymsys, which is a biosimilar of Avastin, is a vascular endothelial growth factor inhibitor used in oncology.

Amneal is introducing Alymsys (bevacizumab-maly), which is a biosimilar of Avastin.

Alymsys is a vascular endothelial growth factor inhibitor used in oncology. This product was developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture and commercialization of biopharmaceuticals.

[Read more: Amneal debuts 2 generics]

“The launch of Alymsys provides additional access and choice to affordable oncology therapeutics for providers and patients. As a new entrant to the fast growing $28 billion U.S. biosimilars market, we are leveraging our commercial expertise in the buy and bill injectable space and have built a dedicated biosimilar commercial team,” said Harsher Singh, senior vice president of Amneal Biosciences. “We look to be an exceptionally customer-centric organization and support stable, system-wide adoption of Alymsys and our biosimilars to come as a long-term player in this space.”

“Amneal has officially entered the U.S. biosimilar market. Beyond these initial launches, we are working to expand our biosimilars portfolio with additional molecules where we can be early to market and vertically integrate over time,” said Chirag and Chintu Patel, co-CEOs. “Biosimilars represent the next wave of affordable medicines and are closely aligned with our mission to provide high quality, affordable medicines to as many patients as possible.”

Bevacizumab had a market value of $2.4 billion, $1.7 billion of which represented biosimilar sales, for the 12 months ending July 2022, according to IQVIA. 

[Read more: FDA approves biosimilar Neupogen]

Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment; metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen; first-line non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel; recurrent glioblastoma in adults; metastatic renal cell carcinoma in combination with interferon alfa; persistent, recurrent or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan; epithelial ovarian, fallopian tube or primary peritoneal cancer, in combination with paclitaxel.

This ad will auto-close in 10 seconds